Radiopharm Theranostics announced positive Phase 2B trial results for RAD101, a diagnostic for brain metastases, meeting its primary endpoint with 93% concordance with MRI. This successful trial paves the way for a Phase 3 pivotal trial and positions the company to address a significant unmet market need in medical imaging.
Radiopharm Theranostics reported that its RAD101 PET diagnostic for brain metastases achieved 93% concordance with MRI in its Phase 2B trial, meeting the primary endpoint. This is a significant positive development for the company as it validates the efficacy of RAD101 and supports its advancement to a Phase 3 pivotal trial in Q4 2026. The filing also highlights a substantial total addressable market of over $600 million with no currently approved PET product, indicating a significant commercial opportunity. This news is a long-term positive catalyst for Radiopharm Theranostics, potentially leading to a new revenue stream and market leadership in brain metastases imaging. The short-term impact could be increased investor confidence and stock price appreciation.